▶ SEMAX · SUBTOPIC · DOSING LITERATURE

SEMAX Dosing Literature

For Laboratory Research Use Only. The content below describes dose ranges as reported in peer-reviewed publications. This page does not recommend any dose for human use. No clinical claim is made. Always consult the original source publication.

SCOPE OF THIS PAGE

This page documents the published-literature dose ranges that appear in trials and animal studies of SEMAX. Every dose mention is bound to a citation (author, year, PMID where available). The PEPPUDEX wiki phrases these as descriptive observations of the research record, not as instructions to the reader.

ROUTES OF ADMINISTRATION IN PUBLISHED RESEARCH

The published research record for SEMAX reports the following route(s) of administration: Intranasal (registered Russian protocol), Subcutaneous (research). Route selection in a study reflects pharmacokinetic considerations specific to that protocol and is not a recommendation for any human use of SEMAX.

PHARMACOKINETIC HALF-LIFE

Published pharmacokinetic data report a half-life for SEMAX of approximately Short (minutes) plasma; intranasal CNS retention longer. Half-life is the kinetic parameter that frames the dosing rhythm chosen in trial design. It is a measurement, not a recommendation.

CITED DOSE RANGES IN THE LITERATURE

The peer-reviewed sources below report dose ranges, frequencies, and durations used in studies of SEMAX. Refer to the original publication for full protocol detail.

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. (2006) reports the SEMAX protocol used in Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus, published in Brain Res. PMID 16996037. See the source for the protocol-level dose range, frequency, and duration. link
Dolotov OV, Karpenko EA, Seredenina TS, et al. (2006) reports the SEMAX protocol used in Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of BDNF in rat basal forebrain, published in J Neurochem. PMID 16635254. See the source for the protocol-level dose range, frequency, and duration. link

DOSING Q+A FROM LITERATURE

The questions below summarise dosing-relevant entries from the literature record. Each answer is descriptive of published material and is not a recommendation.

▶ How does Semax work?

Proposed mechanisms include upregulation of BDNF protein and mRNA in rat hippocampus and basal forebrain after intranasal administration, increased TrkB receptor phosphorylation (canonical signal-transduction event downstream of BDNF), and modulation of serotonin and dopamine turnover in rodent striatum and cortex.

▶ How is Semax administered in Russian clinical practice?

The Russian-approved formulation is a 0.1% intranasal solution. Clinical literature describes 200–600 µg per dose, 1–3 times daily. This wiki does not recommend any human dose.

▶ Side effects of Semax?

Limited Western safety data. Russian literature describes mild nasal irritation and rare headache at standard intranasal doses.

STORAGE OF THE REFERENCE COMPOUND

Lyophilized · 4 °C 12+ months

Reconstituted · 2–8 °C, 28 days

Storage conditions describe the stability of the research-grade reference material, not a dosing protocol.

RECONSTITUTION MATH (CALCULATOR)

The PEPPUDEX reconstitution calculator at /calculator returns volume-per-dose math given vial mg, BAC mL, and a target dose in mcg. The calculator performs arithmetic only. It does not recommend a dose. Any number entered by a researcher must come from their own protocol design or the cited literature.

REGULATORY CONTEXT

FDA · Not FDA-approved. Research-use only in the United States.

WADA · Not currently listed on the WADA Prohibited List (2026).

◀ SEMAX OVERVIEW MECHANISM ▶SAFETY PROFILE ▶

▶ LAST UPDATED · 2026-05-19